The global impact of hepatic fibrosis and end-stage liver disease
- PMID: 18984463
- DOI: 10.1016/j.cld.2008.07.007
The global impact of hepatic fibrosis and end-stage liver disease
Abstract
Hepatic fibrosis is an integral part in the progression of chronic liver disease, ultimately leading to cirrhosis and hepatocellular carcinoma. Globally, alcohol consumption, hepatitis B (HBV) and hepatitis C (HCV) have been the main causes of cirrhosis. More recently, the increasing prevalence of obesity and the metabolic syndrome has resulted in increasing incidence of cirrhosis secondary to nonalcoholic fatty liver disease (NAFLD), especially in developed countries. Chronic liver disease and cirrhosis are important causes of morbidity and mortality in the world. Moreover, the burden of chronic liver disease is projected to increase, due in part to the increasing prevalence of end-stage liver disease and HCC secondary to NAFLD and HCV.
Similar articles
-
The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases.J Med Virol. 2005 Apr;75(4):522-7. doi: 10.1002/jmv.20313. J Med Virol. 2005. PMID: 15714480
-
Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis.Diabetes Metab. 2008 Dec;34(6 Pt 2):634-7. doi: 10.1016/S1262-3636(08)74597-X. Diabetes Metab. 2008. PMID: 19195623
-
Screening for hepatocellular carcinoma: being old is not all bad.Am J Gastroenterol. 2004 Aug;99(8):1477-8. doi: 10.1111/j.1572-0241.2004.40195.x. Am J Gastroenterol. 2004. PMID: 15307863
-
Nonalcoholic fatty liver disease.Minerva Med. 2008 Dec;99(6):583-93. Minerva Med. 2008. PMID: 19034256 Review.
-
Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace.J Hepatol. 2012 Jun;56(6):1384-91. doi: 10.1016/j.jhep.2011.10.027. Epub 2012 Feb 9. J Hepatol. 2012. PMID: 22326465 Review.
Cited by
-
A Clinical Review of Noninvasive Tests for Hepatic Fibrosis.Gastroenterol Hepatol (N Y). 2024 Aug;20(6):322-329. Gastroenterol Hepatol (N Y). 2024. PMID: 39193269 Free PMC article.
-
Assessment of Portal Venous and Hepatic Artery Haemodynamic Variation in Non-Alcoholic Fatty Liver Disease (NAFLD) Patients.J Clin Diagn Res. 2016 Aug;10(8):TC07-10. doi: 10.7860/JCDR/2016/20697.8267. Epub 2016 Aug 1. J Clin Diagn Res. 2016. PMID: 27656524 Free PMC article.
-
Identification of Fast Progressors Among Patients With Nonalcoholic Steatohepatitis Using Machine Learning.Gastro Hep Adv. 2023 Sep 15;3(1):101-108. doi: 10.1016/j.gastha.2023.09.004. eCollection 2024. Gastro Hep Adv. 2023. PMID: 39132186 Free PMC article.
-
Naringenin: A Promising Therapeutic Agent against Organ Fibrosis.Oxid Med Cell Longev. 2021 Nov 11;2021:1210675. doi: 10.1155/2021/1210675. eCollection 2021. Oxid Med Cell Longev. 2021. PMID: 34804359 Free PMC article. Review.
-
Hepatoprotective Effect of Trehalose: Insight into Its Mechanisms of Action.Adv Exp Med Biol. 2021;1328:489-500. doi: 10.1007/978-3-030-73234-9_34. Adv Exp Med Biol. 2021. PMID: 34981500
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical